Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor.
Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.
Tonini
M
M
Department of Physiological and Pharmacological Sciences, University of Pavia, Italy. marcello.tonini@unipv.it
Vigneri
S
S
Savarino
V
V
Scarpignato
C
C
D000897:Anti-Ulcer Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D004347:Drug Interactions; D064098:Esomeprazole; D006801:Humans; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy; D054328:Proton Pump Inhibitors; D016032:Randomized Controlled Trials as Topic; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D009853:Omeprazole; D064098:Esomeprazole